Zoghbi Huda Y reported option exercise involving 7,439 derivative units of REGENERON PHARMACEUTICALS, INC. at $0.00 for $0 on Nov 3, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
7,439Non-Qualified Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 3, 2026Option exercise
Filed
Nov 5, 2026, 4:05 PM ET2-day reporting delay
Accession
0001681643-26-000008Code M · Transaction 393370
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 3, 2026Option exercise7,439$380.95$2,833,887.05Trade 393367
Nov 3, 2026Sell6,939$970.42−$6,733,744.38Trade 393368
Nov 3, 2026Sell500$971.06−$485,530Trade 393369
4 transaction rows in this filing. Joint filers share the same rows.

REGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
REGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −19%1w ago −9.6%1d ago +6.5%
Returns since7d +6.3%30d90d180d1y

Footnotes in full

F1: Represents volume-weighted average price of sales of 6,939 shares of Company stock on November 3, 2026 at prices ranging from $970.00 to $970.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price. F2: Represents volume-weighted average price of sales of 500 shares of Company stock on November 3, 2026 at prices ranging from $971.00 to $971.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price. F3: The stock option vested in three equal annual installments, commencing one year after the date of grant.